共 69 条
[1]
Rosenbrock H(2023)Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia Eur Arch Psychiatry Clin Neurosci 27 559-573
[2]
Desch M(2023)Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia Eur Arch Psychiatry Clin Neurosci 14 1-13
[3]
Wunderlich G(2022)Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor Mol Psychiatry 16 1-18
[4]
Achtyes ED(2023)( Eur Arch Psychiatry Clin Neurosci undefined undefined-undefined
[5]
Hopkins SC(2023))-ketamine attenuates neurodevelopmental disease-related phenotypes in a mouse model of maternal immune activation Eur Arch Psychiatry Clin Neurosci undefined undefined-undefined
[6]
Dedic N(2023)Arketamine for cognitive impairment in psychiatric disorders Eur Arch Psychiatry Clin Neurosci undefined undefined-undefined
[7]
Dworak H(2023)Esmethadone-HCl (REL-1017): a promising rapid antidepressant Eur Arch Psychiatry Clin Neurosci undefined undefined-undefined
[8]
Zeni C(2022)mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development Eur Arch Psychiatry Clin Neurosci undefined undefined-undefined
[9]
Koblan K(2023)Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options Eur Arch Psychiatry Clin Neurosci undefined undefined-undefined
[10]
Wei Y(2023)TDCS at home for depressive disorders: an updated systematic review and lessons learned from a prematurely terminated randomized controlled pilot study Eur Arch Psychiatry Clin Neurosci undefined undefined-undefined